Evaluate averages analysts’ models into one consensus number. Sleuth puts each analyst’s estimate, price target, and note side by side, on top of the drugs, trials, companies, and deals you’d look up in Evaluate.
Every Sleuth plan comes with the drugs, trials, companies, and deals you’d look up in Evaluate. Sleuth then builds the analysis for your question from them.
Landscapes, partner and asset screens, deal comps, and each analyst’s view behind a forecast.
Your team builds financial models every day on its consensus forecasts.
A database subscription
$20K+ a year
The database alone. The analysis is still on you.
Sleuth
From $249 a month
Everything your database has, plus 3,000 credits a month.
Sleuth
Evaluate Pharma
Sleuth
Included in every plan: drugs, trials, companies, and deals in one knowledge base. Browsing is free and doesn’t use credits.
Evaluate Pharma
A yearly license for the datasets you choose, quoted for your team, with no published price.
Sleuth
The standard fields, plus any column you ask for. Ask “who holds the rights outside the US?” and Sleuth adds it as a column, filled in for every program.
Evaluate Pharma
The same fields for every subscriber. A criterion it doesn’t track can’t be added, so you rank against the fields it has.
Sleuth
Click any value to see the filing, registry entry, or broker note behind it, with its date, a confidence score, and whether it’s sourced, inferred, or unknown. Sleuth flags the few cells worth checking.
Evaluate Pharma
You check the records yourself. Its AI assistant cites Evaluate’s own record, not the filing or note behind it.
Sleuth
Each analyst’s estimate, price target, and note side by side, from 35+ research providers.
Evaluate Pharma
One consensus number per drug, averaged from analysts’ models.
Sleuth
Sleuth reads filings, registries, and sell-side research to build the columns needed to answer your question, then the analysis on top.
Evaluate Pharma
Its AI assistant answers from the same fixed fields as the database.
Sleuth
Turn on monitoring, and the dataset updates as trials, filings, and deals come in, with a change log and earlier versions kept.
Evaluate Pharma
You pull the data again each time you need it current.
Sleuth
In every plan. Sleuth builds the analysis from the chat and saves the project to your account.
Evaluate Pharma
Using Evaluate data in your own AI tools takes a separate license.
Sleuth
Analysts’ estimates and price targets, each linked to its note, for a first pass on sizing and comps.
Evaluate Pharma
A standardized consensus series back to 2003, sales by indication, and its own risk-adjusted valuations.
Evaluate gives you one consensus number for each drug. Sleuth reads the notes from 35+ providers and lines up each analyst’s estimate, price target, and reasoning, with a link to the note.
Each analyst’s estimate gets its own row, so you can see how wide the spread is and who sits at each end.
Each view comes with the analyst’s stance, main risk, and a link to the note, so you can tell a bull case from a bear case.
Sleuth puts the forecasts next to the trials, readouts, and deals for the same program.
Evaluate publishes consensus forecasts for almost 6,000 drugs, so most of the early, private, and Chinese programs you’re looking at have no forecast at all. Sleuth has those programs, including about 22,000 from China, read in Chinese.
~22,000
Chinese programs
From China’s registries and filings, read in Chinese
400K+
Companies
Public and private, with Chinese and English names
300K+
Patents
Where early programs often show up first
150K+
Drugs
Every program by target, modality, and phase
Sleuth knowledge base, November 2026.
Evaluate says its AI assistant’s answers “come exclusively from the licensed datasets,” so it can only tell you what’s already in Evaluate’s fields. Sleuth reads the filings, registry entries, and analyst notes behind each record, in Studio or in Claude, ChatGPT, and Copilot.
Our analysts build each Intel Hub report on a Sleuth dataset, with the sell-side research and deals behind it.
Disclosed I&I M&A reached about $325 billion across 172 deals from 2021 through August 2026.
A validated target is now table stakes for ADCs; value is moving to engineering that widens the therapeutic window.
About 1,025 China-originated drugs are approved somewhere in the world, and 34 of them in the US.
Keep Evaluate if your team builds financial models every day on its consensus forecasts. For a first pass on sizing and comps, Sleuth has each analyst’s estimate and price target, linked to its note.
You update your models against a consensus your bankers and board already use.
You check today’s forecasts against consensus history going back years.
You need its risk-adjusted value on each asset, private ones included.
For pipeline, landscape, and deal work, yes: asset screens, competitive landscapes, partner searches, and deal comps. Every plan includes the drugs, trials, companies, and deals you’d look up in Evaluate, and Sleuth builds the analysis on top. Keep Evaluate if your team builds financial models every day on its consensus forecasts.
Analysis built for your question, a knowledge base of drugs, trials, companies, and deals, and searchable documents, including sell-side research from 35+ providers. Browsing the knowledge base and reading the research are free. You can try all of it free for 14 days.
Sleuth shows each analyst’s estimate, price target, and note side by side, so you can see the range and the reasoning. It doesn’t keep a standardized consensus series the way Evaluate does. Keep Evaluate if your team builds financial models every day on its consensus forecasts.
Yes. Its AI assistant’s answers “come exclusively from the licensed datasets,” and each one cites the Evaluate record behind it. Sleuth also reads the filings, registries, and analyst notes behind the records, and links each value to the document it came from.
Every plan includes the drugs, trials, companies, and deals you’d look up in Evaluate. Where Sleuth goes further is China: about 22,000 programs, read in Chinese. Start the free trial and run your own question to compare.
Yes, on every plan. Connect Sleuth, and it builds the analysis from the chat, with a source on every value, and saves each project to your Sleuth account. Using Evaluate data in your own AI tools takes a separate license: in Evaluate’s words, “licensing options are available for organizations looking to integrate Evaluate data into AI-enabled systems and applications.”